Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients

Clinical Pharmacokinetics

Volumn 51, Issue 7, 2012, Pages 467-480

  Moes, Dirk Jan A R ^a   Press, Rogier R ^a   Den Hartigh, Jan ^a   Van Der Straaten, Tahar ^a   De Fijter, Johan W ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

everolimus; pharmacogenetics; pharmacokinetic modelling; population pharmacokinetics; renal transplant

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; EVEROLIMUS; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREGNANE X RECEPTOR;

ABCB1 GENE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CYP2C8 GENE; CYP3A5 GENE; DEMOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; FEMALE; GENE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PXR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; RECEPTORS, STEROID; SIROLIMUS; YOUNG ADULT;

EID: 84861676826     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11599710-000000000-00000     Document Type: Article

References (47)

1. Hö cker B, Tö nshoff B. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Paediatr Drugs 2011 Feb 1; 13 (1): 49-69
2. Pape L, Offner G, Kreuzer M, et al.De novo therapy with everolimus, low-dose ciclosporine A, basiliximab and steroid elimination in pediatric kidney transplantation. Am J Transplant 2010 Oct; 10 (10): 2349-54
3. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009 Aug 15; 88 (3): 421-8
4. Budde K, Lehne G, Winkler M, et al. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol 2005 Jul 1; 45 (7): 781-91 (Pubitemid 40875330)
5. Kacar S, Gurkan A, Karaca C, et al. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Transplant Proc 2010 Nov; 42 (9): 3513-6
6. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011 Mar 5; 377 (9768): 837-47
7. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43 (2): 83-95 (Pubitemid 38283132)
8. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001 Mar; 33 (1-2): 514-5 (Pubitemid 32237488)
9. Istrate MA, Nussler AK, Eichelbaum M, et al. Regulation of CYP3A4 by pregnane X receptor: the role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun 2010 Mar 19; 393 (4): 688-93
10. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant 2011 Feb; 25 (1): 146-50
11. Picard N, Rouguieg-Malki K, Kamar N, et al. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation 2011 Mar 27; 91 (6): 652-6
12. Kovarik JM, Hsu CH, McMahon L, et al. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001 Sep; 70 (3): 247-54 (Pubitemid 32868488)
13. Chan L, Hartmann E, Cibrik D, et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation 2010 Jul 15; 90 (1): 31-7
14. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992 May; 22 (3): 155-63
15. Moes DJAR, Press RR, de Fijter JW, et al. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation. Ther Drug Monit 2010 Aug; 32 (4): 413-9
16. Koster RA, Dijkers ECF, Uges DRA. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood. Ther Drug Monit 2009 Feb; 31 (1): 116-25
17. Lindbom L, Pihlgren P, Jonsson EN, et al. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005 Sep; 79 (3): 241-57 (Pubitemid 41196689)
18. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pirañ a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2010 Jun 1 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/20627442 [Accessed 2010 Sep 21]
19. Karlsson MO, Holford N. A tutorial on visual predictive checks [abstract no. 1434]. Abstracts of the Annual Meeting of the Population Approach Group in Europe (PAGE). PAGE; 2008; Marseille [online]. Available from URL: http://www.page-meeting.org/?abstract=1434 [Accessed 2012 Apr 18]
20. Holford N. The visual predictive check: superiority to standard diagnostic (Rorschach) plots. 2005 [online]. Available from URL: http://www.pagemeeting. org/page/page2005/PAGE2005P105.pdf [Accessed 2012 Apr 18]
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9 (4): 503-12
22. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn 2005 Dec; 32 (5-6): 703-18 (Pubitemid 41781922)
23. IB text Certican. 2004 Mar 30;
24. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004 Oct; 26 (5): 499-505 (Pubitemid 39314317)
25. Kovarik J, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002 Jan 1; 42 (1): 95-9 (Pubitemid 34038374)
26. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001 Jan; 69 (1): 48-56 (Pubitemid 32108671)
27. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer, 2005
28. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol 2010 Jun; 66 (6): 579-90
29. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy 2002 Feb; 22 (2): 154-9 (Pubitemid 34112877)
30. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 2001 Jul; 11 (5): 447-58 (Pubitemid 32656585)
31. Qiu H, Mathä s M, Nestler S, et al. The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genomics 2010 Mar; 20 (3): 167-78
32. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010 Apr 1; 49 (4): 207-21
33. Elens L, Bouamar R, Hesselink DA, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011 Nov; 57 (11): 1574-83
34. Fanta S, Niemi M, Jö nsson S, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008 Feb; 18 (2): 77-90
35. Zhao W, Fakhoury M, Deschênes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 2010 Nov; 50 (11): 1280-91
36. Benkali K, Prémaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48 (12): 805-16
37. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003 Jun; 43 (6): 555-64 (Pubitemid 36613114)
38. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009 Apr; 31 (2): 187-97
39. Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 2009 Dec; 86 (6): 609-18
40. Le Meur Y, Djebli N, Szelag J-C, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 Jul; 80 (1): 51-60 (Pubitemid 43946845)
41. van Schaik RHN, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002 Oct; 48 (10): 1668-71
42. Kang D, Schwartz JB, Verotta D. Sample size computations for PK/PD population models. J Pharmacokinet Pharmacodyn 2005 Dec; 32 (5-6): 685-701 (Pubitemid 41772353)
43. Bertrand J, Comets E, Laffont CM, et al. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn 2009 Aug; 36 (4): 317-39
44. Finnström N, Ask B, Dahl M-L, et al. Intra-individual variation and sex differences in gene expression of cytochromes P450 in circulating leukocytes. Pharmacogenomics J 2002; 2 (2): 111-6 (Pubitemid 34982214)
45. LambaV, Panetta JC, Strom S, et al.Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 2010 Mar; 332 (3): 1088-99
46. Lee C-Y, Lai T-Y, Wu Y-M, et al. Gene expression of P-glycoprotein and cytochrome P450 3A4 in peripheral blood mononuclear cells and correlation with expression in liver. Transplant Proc 2010 Apr; 42 (3): 834-6
47. Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008; 13 (3): 11-8